Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.
暂无分享,去创建一个
F Lampert | J. Harbott | M. Schrappe | C. Bartram | M. Valsecchi | G. Basso | F. Lampert | G. Masera | H. Gadner | M. Aricò | A. Biondi | A. Biondi | A. Reiter | M. Zimmermann | V. Conter | M Aricò | G Basso | A Biondi | M Schrappe | M G Valsecchi | G Masera | H. Riehm | V Conter | M Zimmermann | H Riehm | A Reiter | H Gadner | J Harbott | C R Bartram | M. Valsecchi | H. Gadner | M. Zimmermann
[1] M. Schrappe,et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group. , 1996, Blood.
[2] W. Hiddemann,et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. , 1994, Blood.
[3] J. Harbott,et al. Risk Adapted Treatment in Childhood Acute Lymphoblastic Leukemia: Data from the Berlin-Frankfurt-Münster Group , 1997 .
[4] J. Shuster,et al. Philadelphia chromosome and monosomy 7 in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1991, Blood.
[5] H. Sather,et al. Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Fletcher,et al. Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. , 1991, Blood.
[7] S. Raimondi,et al. Intensive chemotherapy for Philadelphia-chromosome-positive acute lymphoblastic leukaemia , 1994, The Lancet.
[8] F. Behm,et al. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. , 1993, Blood.
[9] J. Ritter,et al. Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) , 1987 .
[10] G. Basso,et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Goldman. The cure model and time confounded risk in the analysis of survival and other timed events. , 1991, Journal of clinical epidemiology.
[12] C. C. Bailey,et al. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X , 1995, The Lancet.
[13] D. Stram,et al. Analysis of time to death after transplantation when transplants are only given to patients in remission. , 1996, Biometrics.
[14] E. Thiel,et al. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction , 1991, The Lancet.
[15] H. Sather,et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. , 1990, Medical and pediatric oncology.
[16] C. Pui,et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. , 1995, Blood.
[17] A Orfao,et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.
[18] Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. , 1991 .
[19] K. Sullivan,et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. , 1997, Blood.
[20] C. Pui,et al. Biology and Clinical Significance of Cytogenetic Abnormalities in Childhood Acute Lymphoblastic Leukemia , 1990 .
[21] R. Pieters,et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia , 1991, The Lancet.
[22] Y. Komada,et al. CD34 antigen expression in children with philadelphia chromosome‐positive acute lymphoblastic leukemia , 1991, Cancer.
[23] W. Kamps,et al. Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM Family" Cooperative Group. , 1992, Medical and pediatric oncology.
[24] J. Harbott,et al. Konzeption und Zwischenergebnis der Therapiestudie ALL-BFM 90 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: Die Bedeutung des initialen Therapieansprechens in Blut und Knochenmark , 1994 .
[25] G. Henze,et al. Abschätzung der Tumorzellmasse bei der akuten lymphoblastischen Leukämie im Kindesalter: prognostische Bedeutung und praktische Anwendung* , 1982 .
[26] J. Harbott,et al. Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[27] F. Behm,et al. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. , 1987, Blood.
[28] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[29] D. Cox. Regression Models and Life-Tables , 1972 .
[30] M. Schrappe,et al. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Horowitz,et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. , 1992, Blood.
[32] S. Raimondi,et al. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: durable responses to chemotherapy associated with low initial white blood cell counts , 1997, Leukemia.
[33] H. Gralnick,et al. Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.
[34] F. Mandelli,et al. Good steroid response in vivo predicts a favorable outcome in children with T‐cell acute lymphoblastic leukemia , 1995 .
[35] M. Schrappe,et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] A. Borkhardt,et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. , 1996, Leukemia.
[37] F. Behm,et al. Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study , 1990 .
[38] A R Zinsmeister,et al. The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL. , 1993, Cancer genetics and cytogenetics.